These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 21601332)
21. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363 [TBL] [Abstract][Full Text] [Related]
23. Novel use of intravenous immunoglobulin G in complement factor H missense mutation: a case report. Neidich AB; Neidich EM; Lee A; Nicoletta J; Rohrer RJ; Milner LS; Cooper JT Prog Transplant; 2013 Sep; 23(3):213-6. PubMed ID: 23996939 [TBL] [Abstract][Full Text] [Related]
24. Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP. Cruzado JM; de Córdoba SR; Melilli E; Bestard O; Rama I; Sánchez-Corral P; López-Trascasa M; Navarro I; Torras J; Gomà M; Grinyó JM Am J Transplant; 2009 Jun; 9(6):1477-83. PubMed ID: 19459807 [TBL] [Abstract][Full Text] [Related]
25. Atypical hemolytic uremic syndrome: telling the difference between H and Y. Goicoechea de Jorge E; Pickering MC Kidney Int; 2010 Oct; 78(8):721-3. PubMed ID: 20877372 [TBL] [Abstract][Full Text] [Related]
26. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. Valoti E; Alberti M; Tortajada A; Garcia-Fernandez J; Gastoldi S; Besso L; Bresin E; Remuzzi G; Rodriguez de Cordoba S; Noris M J Am Soc Nephrol; 2015 Jan; 26(1):209-19. PubMed ID: 24904082 [TBL] [Abstract][Full Text] [Related]
27. Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case. Gnappi E; Allinovi M; Vaglio A; Bresin E; Sorosina A; Pilato FP; Allegri L; Manenti L Pediatr Nephrol; 2012 Oct; 27(10):1995-9. PubMed ID: 22669321 [TBL] [Abstract][Full Text] [Related]
29. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation. Ranch D; Crowther B; Arar M; Assanasen C Pediatr Transplant; 2014 Sep; 18(6):E185-9. PubMed ID: 24931815 [TBL] [Abstract][Full Text] [Related]
30. Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? Noris M; Remuzzi G Nat Clin Pract Nephrol; 2005 Nov; 1(1):2-3. PubMed ID: 16932353 [No Abstract] [Full Text] [Related]
31. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Caillaud C; Zaloszyc A; Licht C; Pichault V; Frémeaux-Bacchi V; Fischbach M Pediatr Nephrol; 2016 Jan; 31(1):157-61. PubMed ID: 26399238 [TBL] [Abstract][Full Text] [Related]
32. Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Tortajada A; Pinto S; Martínez-Ara J; López-Trascasa M; Sánchez-Corral P; de Córdoba SR Kidney Int; 2012 Jan; 81(1):56-63. PubMed ID: 21881555 [TBL] [Abstract][Full Text] [Related]
33. Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. Chaudhary P; Hepgur M; Sarkissian S; Smith RJ; Weitz IC Blood Transfus; 2014 Jan; 12(1):111-3. PubMed ID: 24333077 [No Abstract] [Full Text] [Related]
34. Case Report: Combined Liver-Kidney Transplantation to Correct a Mutation in Complement Factor B in an Atypical Hemolytic Uremic Syndrome Patient. López-Trascasa M; Alonso-Melgar Á; Melgosa-Hijosa M; Espinosa-Román L; Lledín-Barbancho MD; García-Fernández E; Rodríguez de Córdoba S; Sánchez-Corral P Front Immunol; 2021; 12():751093. PubMed ID: 34721423 [TBL] [Abstract][Full Text] [Related]
35. Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation. Pelicano MB; de Córdoba SR; Diekmann F; Saiz M; Herrero S; Oppenheimer F; Campistol JM Transplantation; 2013 Aug; 96(4):e26-9. PubMed ID: 23958887 [No Abstract] [Full Text] [Related]
36. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Kavanagh D; Pappworth IY; Anderson H; Hayes CM; Moore I; Hunze EM; Bennaceur K; Roversi P; Lea S; Strain L; Ward R; Plant N; Nailescu C; Goodship TH; Marchbank KJ Clin J Am Soc Nephrol; 2012 Mar; 7(3):417-26. PubMed ID: 22223611 [TBL] [Abstract][Full Text] [Related]
37. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Boyer O; Balzamo E; Charbit M; Biebuyck-Gougé N; Salomon R; Dragon-Durey MA; Frémeaux-Bacchi V; Niaudet P Am J Kidney Dis; 2010 May; 55(5):923-7. PubMed ID: 20202729 [TBL] [Abstract][Full Text] [Related]
38. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Abarrategui-Garrido C; Melgosa M; Peña-Carrión A; de Jorge EG; de Córdoba SR; López-Trascasa M; Sánchez-Corral P Am J Kidney Dis; 2008 Jul; 52(1):171-80. PubMed ID: 18423815 [TBL] [Abstract][Full Text] [Related]